A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M.
Morschhauser F, et al. Among authors: cartron g.
Ann Oncol. 2008 Feb;19(2):247-53. doi: 10.1093/annonc/mdm463. Epub 2007 Sep 28.
Ann Oncol. 2008.
PMID: 17906297
Free article.
Clinical Trial.